Introduction
Eosinophilic esophagitis (EoE) is a chronic, type 2-associated inflammatory disease of the esophagus that requires invasive endoscopy with biopsies for diagnosis and monitoring. Therefore, non-invasive alternatives have been intensively pursued. Extracellular vesicles (EVs) are nanosize particles virtually released by all cells, which carry biologically meaningful molecules (DNA/RNA, proteins, metabolites) and can be retrieved from biofluids such as blood. EVs emerge as promising, yet largely unexplored source of non-invasive biomarkers in EoE (1).
Aims & Methods
We aimed to identify surface inflammatory markers in circulating EVs (cEVs) with potential diagnostic and monitoring values in EoE, and to explore differences between disease phenotypes (fibrostenotic vs. inflammatory) defined by endoscopic criteria based on the EREFS score or assessed with a functional lumen imaging probe (FLIP) (2). Plasma was collected from patients with EoE (baseline or post-treatment) and control subjects (healthy or atopic); cEVs were isolated by size exclusion chromatography followed by ultrafiltration as previously described (3). Expression of 37 surface inflammatory markers was analyzed by multiplex bead-based flow cytometry across a cohort of 51 participants (29 active EoE, 12 post-treatment EoE, 13 atopic and 9 healthy controls). Markers detected in ≥90% of samples were evaluated. Intergroup differences were tested by uncorrected Dunn or Kruskal–Wallis tests (p<0.05 considered significant), and diagnostic performance was assessed via the area under the ROC curve (AUC).
Results
Clinical characteristics of the patient cohort are shown in Table 1.
Table 1. Main demographic and clinical characteristics of EoE patients and control subjects.
| Active EoE (N=29) | Post-treatment EoE (N=12) | Healthy Controls (N=9) | Atopic Controls (N=13) |
| Age, mean (SD) | 28.2 (10.6)
| 30.4 (12.7)
| 33.1 (11.6)
| 34.8 (9.1)
|
| Male, n (%) | 23 (79)
| 5 (41)
| 5 (55)
| 5 (38)
|
Inflammatory phenotype, n (%) | 18 (62)
| 8 (66)
| * | * |
| Peak of eosinophil/hpf, median (IQR) | 50 (31-66)
| 0 (0-0.75)
| 0 (0-0.25)
| 0 (0-0)
|
Overall EREFS score, median (IQR) | 4 (2.5-5)
| 0 (0-0)
| * | * |
Nine markers met the detection criteria. Clinically relevant significant differences were observed for the tetraspanins CD81 and CD9, and the P-selectin CD62P. CD81 levels were increased in active EoE vs. healthy controls (p=0.008), while CD9 showed the opposite pattern, recovering toward control levels after treatment (p=0.03). CD62P was higher in controls than in active EoE patients (p=0.006), with no significant recovery after treatment, suggesting a link to EoE regardless of inflammatory status.
Differences according to endoscopic phenotype at diagnosis were also assessed (15 fibrostenotic and 26 inflammatory-like patients): CD81 expression was higher in fibrostenotic patients than in controls (p=0.012), but not in inflammatory ones. Similar, yet non-significant trends were observed in atopic controls compared to EoE patients, which is likely due to the limited sample size.
CD62P discriminated EoE patients from controls (AUC=0.72), while CD81 and CD9 distinguished inflammation (active EoE) from non-inflammation (post-treatment EoE, atopic and healthy controls) (AUC=0.70 and AUC=0.68, respectively).
Conclusion
Surface markers on circulating EVs, particularly CD81 and CD9, show potential as non-invasive biomarkers for diagnosis and monitoring of EoE, while CD62P may help identify EoE patients regardless of disease activity. These findings suggest that the immunological profile of cEVs varies with EoE phenotype and inflammation status, and may provide useful information for disease diagnosis and progression. Validation in larger cohorts is warranted.
References
(1)Grueso-Navarro E, Navarro P, Laserna-Mendieta EJ, Lucendo AJ, Arias-González L. Blood-Based Biomarkers for Eosinophilic Esophagitis and Concomitant Atopic Diseases: A Look into the Potential of Extracellular Vesicles. Int J Mol Sci. 2023 Feb 11;24(4):3669.
(2)Casabona-Francés S, Sanz-García A, Ortega GJ, Santander C, Perez-Fernandez T, Majano P, Olalla JM, Juárez-Tosina R, Mueller R, Attwood S, Lucendo A. A New Method to Evaluate Lower Esophageal Distension Capacity in Eosinophilic Esophagitis by Using Functional Lumen Imaging Probe (EndoFLIP™). Diagnostics (Basel). 2024 Jan 19;14(2):218.
(3)Grueso-Navarro E, Rodríguez-Alcolado L, Arias-González L, Aransay AM, Lozano JJ, Sidorova J, Juárez-Tosina R, González-Cervera J, Lucendo AJ, Laserna-Mendieta EJ. MicroRNAs in Plasma-Derived Extracellular Vesicles as Non-Invasive Biomarkers for Eosinophilic Esophagitis. Int J Mol Sci. 2025 Jan 14;26(2):639.